Table 6 Current Combination Chemotherapy for Biliary tract cancer
Author (published year) | Number of Patients | Species of cancer | Regimen | RR (%) | MST (days) | mTTF (days) | Adverse effects (≧Gr3) | Treatment related death |
|---|---|---|---|---|---|---|---|---|
Ishii(2004) | 21 | GBca | CEF(CDDP/5-FU/epirubicin) | 33.3 | 177* | - | hematological toxicity (52.3%) | none |
25 | GBca | FAM(5-FU/Doxorubicin/Mitomycin) | 7.1 | - | hematological toxicity (20%) | none | ||
Lee (2004) | 4 | BDca | Gemsitabine/CDDP | 50 | 270 | 150 | thrombocytopenia (75%) | none |
Doval(2004) | 30 | GBca | Gemsitabine/CDDP | 36.6 | 140 | 126 | nausea/vomiting (16%) | 2 |
Malik(2003) | 11 | GBca | Gemsitabine/CDDP | 64 | 294 | 196 | anemia (45%) | none |
Knox (2004) | 27 | BDca/CBca | Gemsitabine/5-FU | 33 | 159 | 111 | hematological toxicity (11%) | none |
Malik(2003) | 30 | CBca | Leucovorin/5-FU | 7.5 | 444 | 141 | diarrhea (30%) | 1 |
Kim (2003) | 42 | BDca/CBca | Capesitabine/CDDP | 21.4 | 273 | 111 | leucopenia (20%) | none |